BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J. 2008;14:123-127. [PMID: 18391618 DOI: 10.1097/ppo.0b013e31816a6058] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
2 Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong S, Chen W, Yang J, Li H. MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway. Sci Rep 2016;6:22328. [PMID: 26928365 DOI: 10.1038/srep22328] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
3 Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS One 2013;8:e83627. [PMID: 24391798 DOI: 10.1371/journal.pone.0083627] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
4 Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z, Xue C, Liu L, Hu Q, Li J, Cui G, Sun R. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis 2018;9:1045. [PMID: 30315225 DOI: 10.1038/s41419-018-1020-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
5 Rose S, Ezan F, Cuvellier M, Bruyère A, Legagneux V, Langouët S, Baffet G. Generation of proliferating human adult hepatocytes using optimized 3D culture conditions. Sci Rep 2021;11:515. [PMID: 33436872 DOI: 10.1038/s41598-020-80019-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Xiao X, He Q, Huang K. Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy. Med Oncol 2010;27:1200-7. [PMID: 19949900 DOI: 10.1007/s12032-009-9359-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
7 Yang C, Xu Y, Cheng F, Hu Y, Yang S, Rao J, Wang X. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9. Cell Death Dis 2017;8:e2999. [PMID: 28817119 DOI: 10.1038/cddis.2017.356] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
8 Zeng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007;9:951-9. [PMID: 18030363 DOI: 10.1593/neo.07469] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
9 Zhao XX, You FP, Yuan QZ, Pan GZ, Bu QA, Hao L, Zhang J. Safety and effectiveness of radiofrequency combined with laparoscopic cholecystectomy in management of liver cancer near the gallbladder. Shijie Huaren Xiaohua Zazhi 2013; 21(22): 2212-2216 [DOI: 10.11569/wcjd.v21.i22.2212] [Reference Citation Analysis]
10 Guan YS, La Z, Yang L, He Q, Li P. p53 gene in treatment of hepatic carcinoma: Status quoWorld J Gastroenterol 2007; 13(7): 985-992 [PMID: 17373730 DOI: 10.3748/wjg.v13.i7.985] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
11 Orlacchio A, Bolacchi F, Chegai F, Bergamini A, Costanzo E, Del Giudice C, Angelico M, Simonetti G. Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm. Radiol Med. 2014;119:298-308. [PMID: 24277510 DOI: 10.1007/s11547-013-0339-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
12 Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29:130-143. [PMID: 18061252 DOI: 10.1016/j.mam.2007.09.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 4.4] [Reference Citation Analysis]
13 Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L. Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int J Mol Sci 2010;11:1423-33. [PMID: 20480028 DOI: 10.3390/ijms11041423] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
14 Kiran M, Saxena R, Chawla YK, Kaur J. Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Mol Cell Biochem. 2009;327:7-13. [PMID: 19194663 DOI: 10.1007/s11010-009-0035-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
15 Bekeredjian R, Kroll RD, Fein E, Tinkov S, Coester C, Winter G, Katus HA, Kulaksiz H. Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol 2007;33:1592-8. [PMID: 17618040 DOI: 10.1016/j.ultrasmedbio.2007.05.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
16 Yadav V, Panda D, Patidar Y, Bihari C. A rare case report: carcinoma pancreas with hepatocellular carcinoma. Indian J Palliat Care 2014;20:53-6. [PMID: 24600184 DOI: 10.4103/0973-1075.125562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]